VKTX’s Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Viking Therapeutics’ fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

This article was originally published here.